Figure 4
From: PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma
Effect of PPARγ ligands on cell number of prostate cell lines at day 5. Cells were treated with control (0.2% DMSO), troglitazone (100 μM; TGZ), ciglitazone (40 μM; CGZ), rosiglitazone (10 μM; RGZ), pioglitazone (20 μM; PGZ) and 15-deoxy-prostaglandin J2 (5.6 and 10 μM; 15dPGJ2) in the presence or absence of antagonist GW9662 (10 μM) at day 0. A, DU145 cells; B, PC-3 cells; C, LNCaP cells Values are mean ± SEM of two experiments performed in triplicate expressed as percent control. No significant differences were detected following GW9662 treatment for any agent. Statistical significance compared to control * P < 0.01, # P < 0.05 (ANOVA followed by Dunnett post test).